Showing results (351-360 of 534) with videos related to
Sort By:
Pageof 54
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2022
Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results AnalysisAmy M Berkman, Clark R Andersen, Branko Cuglievan, et al.Leukemia|May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDPhilip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.Cancer|March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemiaAlexandre Bazinet, Alex Bataller, Tapan Kadia, et al.Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.American Journal of Hematology|February 27, 2021
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabineKiyomi Morita, Nitin Jain, Hagop Kantarjian, et al.Clinical Lymphoma, Myeloma & Leukemia|February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaGuillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.Blood|October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remissionElias Jabbour, Fadi G Haddad, Nicholas J Short, et al.American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.Leukemia|July 16, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvageRoberta S Azevedo, Elias Jabbour, Nitin Jain, et al.Pageof 54